Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia
NCT01373372 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2019-05-16
Summary
Chronic abdominal pain is the most common persistent pain condition in children and adolescents, affecting 10-15% of children at any given time. One of the most often diagnosed types of abdominal pain is functional dyspepsia (FD). FD is an abdominal pain or discomfort (e.g., nausea, bloating) in the upper abdomen that does not get better by going to the bathroom.
For some people it appears that stress can make FD worse. In adults, stress can cause the release of a hormone called corticotropin releasing hormone (CRH). The release of CRH can cause abdominal pain by affecting how fast things move through a person's stomach and intestines. This makes the organs in the abdomen more sensitive to pain, causing tenderness of the inside lining of the stomach and intestines.
Different people react differently when the body releases CRH. Some people have abdominal pain without feeling any stress or anxiety while other people who have a lot of stress or anxiety don't have any abdominal pain. Some people have neither stress, anxiety, or abdominal pain when CRH is released into the body.
In order to see how the bodies of children with functional dyspepsia and those without functional dyspepsia react to CRH, we will do a CRH stimulation test. A CRH stimulation test is routinely done in endocrine patients. It is not routinely done for patients with functional dyspepsia or for patients who do not have functional dyspepsia.
Part of the CRH stimulation test is giving a synthetic type of corticotropin, Acthrel® (brand name for Corticorelin), as injection. Acthrel® has been approved by the Food and Drug Administration (FDA) for use.
The purpose of this research study is to see if there are differences in how the bodies of children with functional dyspepsia react to CRH versus children who don't have functional dyspepsia.
Being in this study involves one clinic visit where an IV placed and a CRH stimulation test. In this test the child will be given an injection of CRH and then observed for one hour. During that hour the child will have five blood draws through the IV and will be asked questions about their anxiety and abdominal pain. This visit will take about 4 hours.
The following things will happen:
* Your child will be asked to come to the clinic between 8a.m. and 10a.m. fasting. This means your child will have had nothing to eat or drink for 8 hours before coming to the clinic.
* If your child is a female ten years of age or older, or has started having periods, a urine pregnancy test will be done before receiving the CRH infusion.
* You and your child will each be asked to complete a survey that measures your child's anxiety.
* Your child will have a biofeedback session that will measure your child's stress. In a biofeedback session, sensors are placed on your child's fingers, wrists and forehead. These sensors are connected to a computer that monitors your child's heartbeat, skin temperature and electrical pulses on your child's skin.
* Your child will have an IV inserted into a vein in his/her arm. Your child may have a cream put on their arm to help with the pain of the IV insertion. The IV will be used to inject the CRH and draw blood. If the IV stops working and blood samples can no longer be drawn from it, your child may have another IV started or blood samples may be drawn by needle stick.
* Your child will then have 30 minutes to relax.
* Your child will then have CRH infused through the IV over one minute.
* Your child will have blood drawn through the IV five times; right before the CRH stimulation test begins and 15, 30, 45 and 60 minutes after the CRH infusion. The total amount of blood drawn for the study will be about 2 ½ tablespoons.
* Your child will be asked about their abdominal pain, nausea, bloating, stress and anxiety at three separate times during the 60 minutes.
* Your child's heart rate will be measured throughout the CRH stimulation test.
Conditions
- Functional Dyspepsia
Interventions
- DRUG
-
Acthrel
Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
Sponsors & Collaborators
-
Children's Mercy Hospital Kansas City
lead OTHER
Principal Investigators
-
Craig A Friesen, MD · Children's Mercy Hospital and Clinics
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 8 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-12-31
- Primary Completion
- 2016-12-31
- Completion
- 2017-03-31
Countries
- United States
Study Locations
More Related Trials
-
Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients
NCT00249067 ·Status: TERMINATED
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
NCT05201144 ·Status: RECRUITING ·Phase: PHASE2
-
The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease
NCT00480740 ·Status: COMPLETED ·Phase: PHASE3
-
Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
NCT02132195 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Drug Therapy for Pediatric Heart Failure
NCT06039540 ·Status: UNKNOWN
-
Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human
NCT00281762 ·Status: COMPLETED ·Phase: PHASE4
-
Home Inotropic Therapy in Children
NCT00327899 ·Status: TERMINATED
-
Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery
NCT02850250 ·Status: WITHDRAWN
-
Examining Developmental Changes in Heart Contractions of Children With Congenital Heart Defects
NCT00860327 ·Status: TERMINATED
-
Cardiaplication: A Novel Antireflux Operation
NCT02060500 ·Status: COMPLETED ·Phase: NA
-
PRecIsion Medicine in CardiomyopathY
NCT04036799 ·Status: ACTIVE_NOT_RECRUITING
-
Milrinone in Congenital Diaphragmatic Hernia
NCT02951130 ·Status: COMPLETED ·Phase: PHASE2
-
Neuroendocrine Dysfunction in Critically Ill Pediatric Patients
NCT00207896 ·Status: COMPLETED
-
Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease
NCT03417999 ·Status: TERMINATED ·Phase: PHASE1
-
STeroids to REduce Systemic Inflammation After Infant Heart Surgery
NCT03229538 ·Status: COMPLETED ·Phase: PHASE3
-
Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease
NCT02193685 ·Status: RECRUITING
-
Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology
NCT01273857 ·Status: COMPLETED ·Phase: PHASE1
-
Using Tissue Doppler/Synchronization to Determine Heart Function in Children With Congenital Heart Disease
NCT00208676 ·Status: TERMINATED
-
An Evaluation of Routine Developmental Follow-Up in Infants and Children With Congenital Heart Disease
NCT01567579 ·Status: COMPLETED
-
Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease
NCT01821287 ·Status: COMPLETED
-
Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis
NCT00004312 ·Status: COMPLETED
-
Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease
NCT04591171 ·Status: COMPLETED ·Phase: NA
-
Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
NCT03129568 ·Status: COMPLETED ·Phase: PHASE1
-
Heart Failure in Adult Patients With a History of Congenital Heart Disease
NCT00208754 ·Status: TERMINATED
-
New Horizons for the Treatment of Cardiomyopathy in Children
NCT04893629 ·Status: TERMINATED ·Phase: NA